{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:14:40Z","timestamp":1774908880728,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ductal carcinoma in situ, a marginal fraction of the mammary gland diseases, is recognized in 25% of breast cancers detected with mammographic screening. The aim of the study was to assess the prognostic value of Van Nuys Prognostic Index, serving to determine the method of treatment according to the recurrence risk. From the 737 of cases of DCIS detection patients treated in our department in the years 1996\u20132011. The remaining 525 patients whose treatment began from excision of local DCIS and whose further course of treatment was determined after histopathological examination, who were left for observation, treated with lumpectomy and radiotherapy or mastectomy, were qualified for the assessment of mentioned index (Online Appendix 1- Figure S1). The 5-, 10- and 15- year disease recurrence-free survival for the group of 525 patients was 88%, 74% and 62%, respectively. The percentage of 5-, 10- and 15-year disease recurrence-free survival in patients treated in compliance with the VNP Index in individual risk groups did not differ in a statistically significant way. In the low-risk group the percentage of recurrences after local excision, after 5, 10 and 15\u00a0years of observation amounted to 8.8%, 22.8% and 28.8%. In patients from this group, the recurrence risk after breast conserving treatment and mastectomy was 2% and 0%, respectively. VNP Index is not an optimal tool for patients with DCIS. It can be helpful only in some clinically difficult cases as one of methods of assessing the risk of recurrence.<\/jats:p>","DOI":"10.1038\/s41598-021-02126-0","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T06:02:58Z","timestamp":1637560978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of the usefulness of prognostic Van Nuys Prognostic Index in the treatment in ductal carcinoma in situ in 15-year observation"],"prefix":"10.1038","volume":"11","author":[{"given":"Micha\u0142","family":"Kunkiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Niwi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"2126_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgq027","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske, K. Epidemiology of ductal carcinoma in situ. J. Natl. Cancer Inst. Monogr. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq027 (2010).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"2126_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-008-0067-5","volume":"115","author":"LN van Steenbergen","year":"2009","unstructured":"van Steenbergen, L. N. et al. Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 115, 181\u2013183. https:\/\/doi.org\/10.1007\/s10549-008-0067-5 (2009).","journal-title":"Breast Cancer Res. Treat."},{"key":"2126_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.breast.2016.09.001","volume":"31","author":"EJ Groen","year":"2017","unstructured":"Groen, E. J. et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast (Edinburgh, Scotland) 31, 274\u2013283. https:\/\/doi.org\/10.1016\/j.breast.2016.09.001 (2017).","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"2126_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv263","author":"M Worni","year":"2015","unstructured":"Worni, M. et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv263 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"2126_CR5","doi-asserted-by":"publisher","unstructured":"Ponti, A. et al. International variation in management of screen-detected ductal carcinoma in situ of the breast. Eur. J. Cancer (Oxford, England : 1990) 50, 2695\u20132704, doi:https:\/\/doi.org\/10.1016\/j.ejca.2014.07.019 (2014).","DOI":"10.1016\/j.ejca.2014.07.019"},{"key":"2126_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-011-1387-4","volume":"127","author":"SY Wang","year":"2011","unstructured":"Wang, S. Y., Shamliyan, T., Virnig, B. A. & Kane, R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res. Treat. 127, 1\u201314. https:\/\/doi.org\/10.1007\/s10549-011-1387-4 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"2126_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/jco.2011.36.4976","volume":"30","author":"M Yi","year":"2012","unstructured":"Yi, M. et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J. Clin. Oncol. 30, 600\u2013607. https:\/\/doi.org\/10.1200\/jco.2011.36.4976 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2126_CR8","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/(sici)1097-0142(19960601)77:11<2267::aid-cncr13>3.0.co;2-v","volume":"77","author":"MJ Silverstein","year":"1996","unstructured":"Silverstein, M. J. et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 77, 2267\u20132274. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19960601)77:11%3c2267::aid-cncr13%3e3.0.co;2-v (1996).","journal-title":"Cancer"},{"key":"2126_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s0002-9610(03)00265-4","volume":"186","author":"MJ Silverstein","year":"2003","unstructured":"Silverstein, M. J. The university of southern California\/van nuys prognostic index for ductal carcinoma in situ of the breast. Am. J. Surg. 186, 337\u2013343. https:\/\/doi.org\/10.1016\/s0002-9610(03)00265-4 (2003).","journal-title":"Am. J. Surg."},{"key":"2126_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgq040","author":"MJ Silverstein","year":"2010","unstructured":"Silverstein, M. J. & Lagios, M. D. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California\/Van Nuys Prognostic Index. J. Natl. Cancer Inst. Monogr. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq040 (2010).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"2126_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/tbj.12368","volume":"21","author":"MJ Silverstein","year":"2015","unstructured":"Silverstein, M. J. & Lagios, M. D. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California\/Van Nuys (USC\/VNPI) prognostic index. Breast J. 21, 127\u2013132. https:\/\/doi.org\/10.1111\/tbj.12368 (2015).","journal-title":"Breast J."},{"key":"2126_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","volume":"152","author":"E Rakovitch","year":"2015","unstructured":"Rakovitch, E. et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res. Treat. 152, 389\u2013398. https:\/\/doi.org\/10.1007\/s10549-015-3464-6 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"2126_CR13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.ajpath.2018.12.003","volume":"189","author":"S Nofech-Mozes","year":"2019","unstructured":"Nofech-Mozes, S., Hanna, W. & Rakovitch, E. Molecular evaluation of breast ductal carcinoma in situ with oncotype DX DCIS. Am. J. Pathol. 189, 975\u2013980. https:\/\/doi.org\/10.1016\/j.ajpath.2018.12.003 (2019).","journal-title":"Am. J. Pathol."},{"key":"2126_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10549-017-4553-5","volume":"167","author":"RS Punglia","year":"2018","unstructured":"Punglia, R. S. et al. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res. Treat. 167, 751\u2013759. https:\/\/doi.org\/10.1007\/s10549-017-4553-5 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"2126_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1445-2197.2012.06133.x","volume":"82","author":"R Whitfield","year":"2012","unstructured":"Whitfield, R., Kollias, J., de Silva, P., Turner, J. & Maddern, G. Management of ductal carcinoma in situ according to Van Nuys Prognostic Index in Australia and New Zealand. ANZ J. Surg. 82, 518\u2013523. https:\/\/doi.org\/10.1111\/j.1445-2197.2012.06133.x (2012).","journal-title":"ANZ J. Surg."},{"key":"2126_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.ejso.2016.05.024","volume":"42","author":"Results of the Mammary Fold National Practice Survey","year":"2016","unstructured":"Results of the Mammary Fold National Practice Survey. Variation in the management of ductal carcinoma in situ in the UK. Eur. J. Surg. Oncol. 42, 1153\u20131161. https:\/\/doi.org\/10.1016\/j.ejso.2016.05.024 (2016).","journal-title":"Eur. J. Surg. Oncol."},{"key":"2126_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1477-7819-6-61","volume":"6","author":"O Gilleard","year":"2008","unstructured":"Gilleard, O., Goodman, A., Cooper, M., Davies, M. & Dunn, J. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J. Surg. Oncol. 6, 61. https:\/\/doi.org\/10.1186\/1477-7819-6-61 (2008).","journal-title":"World J. Surg. Oncol."},{"key":"2126_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bjs.4051","volume":"90","author":"GP Boland","year":"2003","unstructured":"Boland, G. P., Chan, K. C., Knox, W. F., Roberts, S. A. & Bundred, N. J. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br. J. Surg. 90, 426\u2013432. https:\/\/doi.org\/10.1002\/bjs.4051 (2003).","journal-title":"Br. J. Surg."},{"key":"2126_CR19","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/cncr.23089","volume":"110","author":"SG MacAusland","year":"2007","unstructured":"MacAusland, S. G. et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110, 2648\u20132653. https:\/\/doi.org\/10.1002\/cncr.23089 (2007).","journal-title":"Cancer"},{"key":"2126_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10549-007-9668-7","volume":"109","author":"S Di Saverio","year":"2008","unstructured":"Di Saverio, S. et al. 259 patients with DCIS of the breast applying USC\/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res. Treat. 109, 405\u2013416. https:\/\/doi.org\/10.1007\/s10549-007-9668-7 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"2126_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-019-0777-3","volume":"21","author":"LJ Solin","year":"2019","unstructured":"Solin, L. J. Management of ductal carcinoma in situ (dcis) of the breast: present approaches and future directions. Curr. Oncol. Rep. 21, 33. https:\/\/doi.org\/10.1007\/s11912-019-0777-3 (2019).","journal-title":"Curr. Oncol. Rep."},{"key":"2126_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2017.00248","volume":"7","author":"KL Gorringe","year":"2017","unstructured":"Gorringe, K. L. & Fox, S. B. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front. Oncol. 7, 248. https:\/\/doi.org\/10.3389\/fonc.2017.00248 (2017).","journal-title":"Front. Oncol."},{"key":"2126_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/jso.20711","volume":"95","author":"TA Buchholz","year":"2007","unstructured":"Buchholz, T. A., Haffty, B. G. & Harris, J. R. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J. Surg. Oncol. 95, 610\u2013613. https:\/\/doi.org\/10.1002\/jso.20711 (2007).","journal-title":"J. Surg. Oncol."},{"key":"2126_CR24","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/jco.2016.68.3573","volume":"34","author":"M Morrow","year":"2016","unstructured":"Morrow, M. et al. Society of surgical oncology-american society for radiation oncology-american society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J. Clin. Oncol. 34, 4040\u20134046. https:\/\/doi.org\/10.1200\/jco.2016.68.3573 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2126_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","volume":"103","author":"IL Wapnir","year":"2011","unstructured":"Wapnir, I. L. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J. Natl Cancer Inst. 103, 478\u2013488. https:\/\/doi.org\/10.1093\/jnci\/djr027 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"2126_CR26","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/jco.2013.49.5077","volume":"31","author":"M Donker","year":"2013","unstructured":"Donker, M. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J. Clin. Oncol. 31, 4054\u20134059. https:\/\/doi.org\/10.1200\/jco.2013.49.5077 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2126_CR27","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/jco.2014.56.2595","volume":"32","author":"F W\u00e4rnberg","year":"2014","unstructured":"W\u00e4rnberg, F. et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J. Clin. Oncol. 32, 3613\u20133618. https:\/\/doi.org\/10.1200\/jco.2014.56.2595 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2126_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick, J. et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol. 12, 21\u201329. https:\/\/doi.org\/10.1016\/s1470-2045(10)70266-7 (2011).","journal-title":"Lancet Oncol."},{"key":"2126_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/jco.2014.57.9029","volume":"33","author":"B McCormick","year":"2015","unstructured":"McCormick, B. et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J. Clin. Oncol. 33, 709\u2013715. https:\/\/doi.org\/10.1200\/jco.2014.57.9029 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2126_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000563.pub7","author":"A Goodwin","year":"2013","unstructured":"Goodwin, A., Parker, S., Ghersi, D. & Wilcken, N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. The Cochrane database of systematic reviews https:\/\/doi.org\/10.1002\/14651858.CD000563.pub7 (2013).","journal-title":"The Cochrane database of systematic reviews"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02126-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:30:01Z","timestamp":1670070601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02126-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2126"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02126-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-603310\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22645"}}